MCKESSON CORPORATION (MCK)
Balfour Capital Group Researched McKesson Corp on September 11th, 2023.
McKesson Corp (MCK), a healthcare services and pharmaceutical distribution company, plays a vital role in the healthcare supply chain, ensuring access to medicines and healthcare solutions globally.
Post Recommendation Price Trend Chart The chart's commencement marks the instance of our stock recommendation.
- We have established a Buy recommendation at $420.78 on September 11th, 2022.
- Our designated price target stands at $480.00.
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
THOMSON REUTERS ON MCK
THOMSON REUTERS
VIEW MOREARGUS ANALYST ON MCK
ARGUS ANALYST NOTES
VIEW MOREARGUS QUANTITIVE ON MCK
ARGUS QUANTITIVE REPORT
VIEW MOREMORGAN STANLEY ON MCK
MORGAN STANLEY NOTES
VIEW MORE2024 Q2 EARNING REPORT
Earnings Report
VIEW MORECOMPANY SNAPSHOT
COMPANY SNAPSHOT
VIEW MOREBalfour Capital Group wants to clarify that our recommendation to Buy MCKESSON CORPORATION (MCK) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*